Phosphagen. Share Discussion Threads

[joe moon] 24/8/2006 23:50

i have made 30 quid on this today

[suesean1] 24/8/2006 23:50

UK Analyst

Shares in Phosphagenics jumped 2p to 15.5p after the company unveiled potentially very exciting results from one of its trials. The group said that the interim results from its Phase I transdermal insulin clinical trial demonstrated that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2. It said that from one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time

[suesean1] 24/8/2006 23:45

Business Strategy
Financial News
Generics
Legal Actions
Patent Issues
Agency News
Electronic Marketing
Product Marketing News
Cardiovascular
Oncology
Pain & Inflammation
Central Nervous System
Infectious Disease
Contract Research Business
Drug Approvals
Drug Discovery
Drugs In Development
eR&D
Filed For Approval
Trial Results
Regulatory Actions
Warnings
FDA Policy
Investment Banking Healthcare
Medical/Professional


TRIAL RESULTS



Phosphagenics Successfully Delivers Insulin Across the Skin in Humans



No adverse reactions reported



Key points:


* TPM-02/Insulin applied as a gel delivered insulin through the skin and into the bloodstream

* TPM-02/Insulin significantly lowered blood glucose levels

* TPM-02/Insulin did not produce any adverse reactions

* TPM-02 carrier platform has now shown the ability to deliver large molecules (e.g. proteins) through the skin in humans

MELBOURNE, Australia, Aug. 24, 2006--Phosphagenics Limited ("Phosphagenics") (AIM:PSG; ASX: POH) announced today the interim results from its Phase I transdermal insulin clinical trial, demonstrating that it had successfully delivered insulin through the skin in a way that could radically alter patient care for many diabetics around the world, especially those with Type 2.


>From one topical application of TPM-02/Insulin applied as a gel, insulin was shown to safely penetrate the human skin and then be delivered into the blood stream over a sustained period of time.


Dr William Hsu, co-investigator for this trial and clinician at the Joslin Diabetes Center of the Harvard Medical School, Boston, USA, said the trial results are evidence of the safety and tolerability of TPM-02/Insulin and demonstrate that this technology can deliver large molecules such as proteins through the skin.


"The primary objective was to confirm the safety and tolerability of TPM-02/Insulin, and this was achieved with no adverse reactions," Dr Hsu said.


"The trial also demonstrated the ability of TPM-02/Insulin to deliver insulin into the blood stream at levels high enough to produce significant effects. This is a very impressive result, given that it was administered as a single dose to healthy volunteers.


"This technology could eventually transform and expand the world's multi-billion dollar insulin market by providing a non-invasive and effective treatment for many of the world's 194 million diabetics, the majority of which are classified as Type 2," he said.


In the study, 20 healthy male volunteers, aged between 18 and 45, fasted overnight and then randomly received a single dose of TPM-02/Insulin or a placebo gel, applied directly onto the skin. Volunteers were then monitored for a period of 48 hours to assess the primary endpoint of safety.


Conducted at the Centre for Clinical Studies in Melbourne, Australia, and in accordance with ICH GCP standards and under the guidance and supervision of Professor Leon Bach, blood glucose and insulin levels, and the insulin biomarker C-peptide were all measured as secondary endpoints.


"To see TPM-02/Insulin produce a statistically significant and sustained effect on key markers, such as blood glucose concentration, insulin, and C-peptide is very encouraging and warrants significant future development," Dr Hsu said.


Dr Esra Ogru, Executive Director of Research and Development at Phosphagenics, said that this was a milestone for Phosphagenics and allows it to now move rapidly into its next stage of development with TPM-02/Insulin.


"With this success we will now start exploring ways to apply this technology to other pharmaceutical products, as well as developing other routes of administration, such as oral and inhalation," Dr Ogru said.


Phosphagenics Managing Director, Harry Rosen added: "This result supports our recent focus on developing this novel patented technology. We expect this development to enhance international interest in Phosphagenics' technology as it is a key milestone in the delivery of large molecules effectively and safely through the skin

[outsizeclothes.com] 24/8/2006 10:55

Reading their website, Estseon, on TPM-02 - mostly hormone fragments.
TPM-01 has the much wider product transport range.

[estseon] 24/8/2006 10:06

Still a long way to go on clinical trials but I wonder what other large protein molecules might use that transporter base?

[hectorp] 24/8/2006 07:53

'Are you aware of anything that could have started this change in the shares price' ?
answer -
NO.
- come on, this leaked like a seive last week.

Well done holders, and this seems a very good product, but I suspect anyone wanting in now should be waiting for the dust to settle.

[flintsurfer] 24/8/2006 05:09

Bonjour
Here is the link to the news we wanted -big vol in Aus. Up 7%



I suggest this will be 20p in next 2 weeks
At last!

[suesean1] 23/8/2006 08:37

LONDON (AFX) - AIM-listed Australian pharma group Phosphagenics Ltd said it
is aware that an offshore financial institution has acquired a parcel of
Phosphagenics' shares last week.
In response to an ASX query on the movement of its share price, the company
said another reason the rise in the price and volume of its shares could be due
to the Phase 1 clinical trial of its patented transdermal insulin delivery
platform.
As previously announced, receipt of the full analysis of the trial is
expected by September, as expected.
Phosphagenics is also expecting a preliminary report from the principle
investigator shortly and will subsequently release details of this report.
Further, as announced, the company said it expects operating loss before
abnormal items and tax for the half year to June to vary materially -- about 1.2
mln aud greater -- from the previous corresponding period.
[e-mail]

[suesean1] 23/8/2006 08:24

5. Is there any other explanation that the Company may have for the price
change and increase in volume in the securities of the Company

Answer

5. Phosphagenics suggests that the following may provide some explanation for
the price changes and increase in volume in the securities of the Company:

A) Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

B) As previously reported to ASX on 24 July 2006 the Company commenced a
pivotal Phase I clinical trial its patented transdermal insulin delivery
platform. That announcement stated that the trial was expected to be completed
by the end of July with full analysis anticipated by September 2006. The
Company has no reason to expect that the receipt of the full analysis of the
trial and any consequence announcement to the ASX will not be within the
original time frame disclosed in the 24 July 2006 announcement. The Company is
also expecting a preliminary report from the principle investigator shortly and
will subsequently release details of this report


Could we have a Predator on the prowl ?!?!

[suesean1] 23/8/2006 07:59

23 August 2006

Phosphagenics Limited

On 22 August 2006, the Australian Stock Exchange ("ASX") published a response
by the Company to an ASX query regarding a change in the Company's share price.
Both the published query and response are set out below:

Query:

21 August 2006

Mourice Garbutt

Company Secretary

Phosphagenics Limited

By Email only

Dear Mourice

Phosphagenics Limited (the "Company")

RE: PRICE QUERY

We have noted a change in the price of the Company's securities from a low of
$0.29 on 7 August 2006 to $0.365 at the time of writing. We have also noted an
increase in the volume of trading in the securities over this period.

In light of the price change and increase in volume, please respond to each of
the following questions.

1. Is the Companyaware of any information concerning it that has not been
announced which, if known, could be an explanation for recent trading in
the securities of the Company?

2. If the answer to question 1 is yes, can an announcement be made
immediately? If not, why not and when is it expected that an announcement
will be made?

Please note, if the answer to question 1 is yes and an announcement cannot be
made immediately, you need to contact us to discuss this and you need to
consider a trading halt (see below).

3. Is there any reason to think that there may be a change in the operating
loss before abnormal items and income tax so that the figure for the half year
ended 30 June 2006 would vary materially from the previous corresponding
period. If so, please provide details as to the extent of the likely variation.

4. Is there any reason to think that the Company may record any material
abnormal or extraordinary items for the half year ended 30 June 2006? If so,
please provide details.

5. Is there any other explanation that the Company may have for the price
change and increase in volume in the securities of the Company?

6. Please confirm that the Company is in compliance with the listing rules and,
in particular, listing rule 3.1.

Your response should be sent to me by return e-mail or by facsimile on
facsimile number [phone]. It should not be sent to the Company
Announcements Office.

Unless the information is required immediately under listing rule 3.1, a
response is requested as soon as possible and, in any event, not later than
half an hour before the start of trading (ie before 9.30 a.m. ) on Tuesday, 22
August 2006).

Under listing rule 18.7A, a copy of this query and your response will be
released to the market, so your response should be in a suitable form and
separately address each of the questions asked. If you have any queries or
concerns, please contact me immediately.

Listing rule 3.1

Listing rule 3.1 requires an entity to give ASX immediately any information
concerning it that a reasonable person would expect to have a material effect
on the price or value of the entity's securities. The exceptions to this
requirement are set out in listing rule 3.1A.

In responding to this letter you should consult listing rule 3.1 and Guidance
Note 8 - Continuous Disclosure: listing rule 3.1.

If the information requested by this letter is information required to be given
to ASX under listing rule 3.1 your obligation is to disclose the information
immediately.

Your responsibility under listing rule 3.1 is not confined to, or necessarily
satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond by the time requested, or if the answer to
question 1 is yes and an announcement cannot be made immediately, you should
consider a request for a trading halt in the Company's securities. As set out
in listing rule 17.1 and Guidance Note 16 - Trading Halts we may grant a
trading halt at your request. We may require the request to be in writing. We
are not required to act on your request. You must tell us each of the
following.

* The reasons for the trading halt.

* How long you want the trading halt to last.

* The event you expect to happen that will end the trading halt.

* That you are not aware of any reason why the trading halt should not be
granted.

* Any other information necessary to inform the market about the trading
halt, or that we ask for.

The trading halt cannot extend past the commencement of normal trading on the
second day after the day on which it is granted. If a trading halt is requested
and granted and you are still unable to reply to this letter before the
commencement of trading, suspension from quotation would normally be imposed by
us from the commencement of trading if not previously requested by you. The
same applies if you have requested a trading halt because you are unable to
release information to the market, and are still unable to do so before the
commencement of trading.

If you have any queries regarding any of the above, please let me know.

Yours faithfully,

Julia Kagan

Adviser, Issuers (Melbourne)



Response:

22 August 2006


Ms Julia Kagan

Adviser, Issuer (Melbourne)

Australian Stock Exchange Limited

Level 3, Stock Exchange Centre

530 Collins Street

Melbourne Vic 3000


Dear Julia

Re: Phosphagenics Limited - Price Query

In response to your letter of 21 August the Company advises the following
responses:

1. No

2. Not applicable

3. As previously disclosed to ASX in the Company's 2005 Annual Report and
various announcements to ASX since that time, Phosphagenics has accelerated its
research programme, particularly its clinical (human) studies. In line with
this acceleration, Phosphagenics anticipates that the operating loss before
abnormal items and income tax for the half year ended 30 June 2006 will vary
materially (about $1.2 million greater) from the previous corresponding period.

4. No

5. Phosphagenics suggests that the following may provide some explanation for
the price changes and increase in volume in the securities of the Company:

A) Phosphagenics is aware that an offshore financial institution has acquired a
parcel of Phosphagenics' shares last week.

B) As previously reported to ASX on 24 July 2006 the Company commenced a
pivotal Phase I clinical trial its patented transdermal insulin delivery
platform. That announcement stated that the trial was expected to be completed
by the end of July with full analysis anticipated by September 2006. The
Company has no reason to expect that the receipt of the full analysis of the
trial and any consequence announcement to the ASX will not be within the
original time frame disclosed in the 24 July 2006 announcement. The Company is
also expecting a preliminary report from the principle investigator shortly and
will subsequently release details of this report.

6. We confirm the Company is in compliance with the Listing Rules, and in
particular Listing Rule 3.1.


Yours Faithfully

Phosphagenics Limited


Per Mourice Garbutt

Company Secretary


For further information please contact:

Rowan Minnion
Northbank Communications

[e-mail]

[cmp2] 21/8/2006 22:58

for the fist time in ages I am now in profit with PSG...
this slow and steady build up may be the prelude to a rerating of this completly overlooked stock.
I note orbis have built a substantial holding....they are shrewd investors...

[flintsurfer] 21/8/2006 03:47

Good vol too

[suesean1] 21/8/2006 01:49

4.35% up in aus as i type, looking good for later on!

[flintsurfer] 20/8/2006 06:35

I believe I posted that a few days back (ref the one eyed man)!
Pity my only top up was at 11p and the bulk at 15p!
The next few weeks/month(s) could prove rather pivotal for us holders of OEX/OXB/PSG!

[elfman] 19/8/2006 23:05

Said 13p by end of week :0)

My prediction for next week is 20p ;0) (I can dream).

[rambutan2] 17/8/2006 23:54

hi suesean,

yes, am happy to sit and wait.

[suesean1] 17/8/2006 10:22

Notice the chart at the start of 04, four steps then a massive spike. will we see the same again!

Not a chartist.

[elfman] 17/8/2006 10:11

The principal investigator to the clinical trial will be Professor Leon Bach,
senior endocrinologist at The Alfred hospital (Melbourne, Australia)

Wonder if news looking good? Trials finished by July, results in sep. Does someone know something? Definately. Is that the cause of the rise? Impossible to know. We don't even know what the results are.

:0)

[suesean1] 17/8/2006 09:34

6.5% up in Aus and over 7 million volume. Looking good!!

rambutan, you still about?

[elfman] 16/8/2006 08:15

this time next year rodney!

[spaceparallax] 15/8/2006 12:53

It certainly makes pleasant viewing - carry on that way for a couple of years and we could be millionaires!

[elfman] 15/8/2006 12:16

If the graph continues on it's current track we will get another tick up this week.

Fingers crossed :0)

[spaceparallax] 11/8/2006 12:25

Hi Elf,

SP progress is pleasing, albeit perhaps a little surprising, in advance of the results. IF those results live upto expectations, I would not be surprised to see us move to 20p.

[elfman] 11/8/2006 10:34

Continues to tick up nicely. Chart indicating we should get to 13p before results of early phase 1 trial. If this is positive we may get a good response to share price as the market seems to be increasing value gradually ie seem to be more aware of company. If instit start to buy into the story we could get some dramatic share price movements.

All IMO.